Какова цена за Enochian Biosciences, Inc. (ENOB)

Цена за Enochian Biosciences, Inc. (ENOB) Это $2.60

Какова рыночная капитализация для Enochian Biosciences, Inc. (ENOB)

Рыночная капитализация для Enochian Biosciences, Inc. (ENOB) Это $145.54M

Enochian Biosciences, Inc. (ENOB) Коэффициент P/E

Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase. Beyond these primary programs, Enochian Biosciences' developmental pipeline also features ENOB-DC-11, an off-the-shelf dendritic cell vaccine designed for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for direct intratumoral injection. The company collaborates strategically with prominent research organizations such as The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Founded in 2017, Enochian Biosciences, Inc. operates from its headquarters in Los Angeles, California.

Год	P/E коэффициент	Изменить
Недостаточно данных для указанных дат.

Год

P/E коэффициент

Изменить

Недостаточно данных для указанных дат.

Компания	P/E Ratio	Разница P/E	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
Moderna, Inc. MRNA.US	-7.93	-	US
CSL Limited CSL.AX	32.46	-	AU
Lonza Group AG LONN.SW	-	-	CH

Компания

P/E Ratio

Разница P/E

Страна